Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer

BACKGROUND: There has been remarkable progress in systemic chemotherapy for metastatic colorectal cancer due to the widespread use of irinotecan, oxaliplatin, anti-vascular endothelial growth factor antibody, and anti-epidermal growth factor receptor antibody. It is important to continue treatment w...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotaka, Masahito, Ikeda, Fusao, Tsujie, Masaki, Yoshioka, Shinichi, Nakamoto, Yoshihiko, Ishii, Takaaki, Kyogoku, Takahisa, Kato, Takeshi, Tsuji, Akihito, Kobayashi, Michiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944910/
https://www.ncbi.nlm.nih.gov/pubmed/27468238
http://dx.doi.org/10.2147/OTT.S104140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944910/
https://www.ncbi.nlm.nih.gov/pubmed/27468238
http://dx.doi.org/10.2147/OTT.S104140

Ejemplares similares